Modulating the immune response in demyelinating diseases.
作者信息
Hughes R
出版信息
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):148. doi: 10.1136/jnnp.64.2.148.
Abstract
摘要
相似文献
1
Modulating the immune response in demyelinating diseases.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):148. doi: 10.1136/jnnp.64.2.148.
2
Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):162-5. doi: 10.1136/jnnp.64.2.162.
3
Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):148-9. doi: 10.1136/jnnp.64.2.148a.
4
5
Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome?
J Clin Apher. 1995;10(3):150-7. doi: 10.1002/jca.2920100310.
6
A practical approach to the use of intravenous immunoglobulin in neurological disease.
Eur Neurol. 1998;39(1):3-8. doi: 10.1159/000007891.
7
Future developments in the treatment of immune-mediated polyneuropathies.
Eur Neurol. 1997;38(3):230-7. doi: 10.1159/000113378.
8
Rational therapy of Guillain-Barré syndrome.
Lancet. 1998 Mar 7;351(9104):753-4. doi: 10.1016/s0140-6736(05)78527-5.
9
Root stimulation improves the detection of acquired demyelinating polyneuropathies.
Muscle Nerve. 1998 Mar;21(3):298-308. doi: 10.1002/(sici)1097-4598(199803)21:3<298::aid-mus3>3.0.co;2-5.
10
Anti-D immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy.
J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):383-4. doi: 10.1136/jnnp.58.3.383-a.
Zotero 插件